Zobrazeno 1 - 10
of 20
pro vyhledávání: '"Shadia Jalal"'
Autor:
Zhen Hua, Zhe Li, Dawith Lim, Ali Ajrouch, Ahmad Karkash, Shadia Jalal, Michael Childress, John Turek, David Nolte
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-10 (2024)
Abstract Nearly half of cancer patients who receive standard-of-care treatments fail to respond to their first-line chemotherapy, demonstrating the pressing need for improved methods to select personalized cancer therapies. Low-coherence digital holo
Externí odkaz:
https://doaj.org/article/ecb97f01263b46f697e0eb427e97218f
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss 3 (2023)
Background Myeloid-derived suppressor cells (MDSCs) are a heterogeneous population of cells in tumor microenvironment, which suppress antitumor immunity. Expansion of various MDSC subpopulations is closely associated with poor clinical outcomes in ca
Externí odkaz:
https://doaj.org/article/00d3abdfa7784ec3b9486a29126b5b15
Autor:
Kathryn F. Mileham, Caroline Schenkel, Suanna S. Bruinooge, Janet Freeman‐Daily, Upal Basu Roy, Amy Moore, Robert A. Smith, Elizabeth Garrett‐Mayer, Lauren Rosenthal, Edward B. Garon, Bruce E. Johnson, Raymond U. Osarogiagbon, Shadia Jalal, Shamsuddin Virani, Mary Weber Redman, Gerard A. Silvestri
Publikováno v:
Cancer Medicine, Vol 11, Iss 2, Pp 530-538 (2022)
Abstract Background An ASCO taskforce comprised of representatives of oncology clinicians, the American Cancer Society National Lung Cancer Roundtable (NLCRT), LUNGevity, the GO2 Foundation for Lung Cancer, and the ROS1ders sought to: characterize U.
Externí odkaz:
https://doaj.org/article/77e04cdb969842218b3ff0a67980c00e
Autor:
Andrea M Chambers, Kyle B Lupo, Jiao Wang, Jingming Cao, Sagar Utturkar, Nadia Lanman, Victor Bernal-Crespo, Shadia Jalal, Sharon R Pine, Sandra Torregrosa-Allen, Bennett D Elzey, Sandro Matosevic
Publikováno v:
eLife, Vol 11 (2022)
Immunometabolic reprogramming due to adenosine produced by CD73 (encoded by the 5’-ectonucleotidase gene NT5E) is a recognized immunosuppressive mechanism contributing to immune evasion in solid tumors. Adenosine is not only known to contribute to
Externí odkaz:
https://doaj.org/article/97d6c81764a042458eef5e324c28f106
Autor:
Valentina Boni, Mary J. Fidler, Hendrik-Tobias Arkenau, Alexander Spira, Funda Meric-Bernstam, Nataliya Uboha, Rachel E. Sanborn, Randy F. Sweis, Patricia LoRusso, Misako Nagasaka, Javier Garcia-Corbacho, Shadia Jalal, James J. Harding, Stella K. Kim, Iris H.C. Miedema, Danielle J. Vugts, Marc C. Huisman, Gerben J.C. Zwezerijnen, Guus A.M.S. van Dongen, C. Willemien Menke van der Houven van Oordt, Song Wang, Tam Dang, Ivan A. Zein, Olga Vasiljeva, Susan K. Lyman, Virginia Paton, Alison Hannah, Joyce F. Liu
Publikováno v:
Clinical Cancer Research, 28(10), 2020-2029. American Association for Cancer Research Inc.
Purpose: Praluzatamab ravtansine (CX-2009) is a conditionally activated Probody drug conjugate (PDC) comprising an anti-CD166 mAb conjugated to DM4, with a protease-cleavable linker and a peptide mask that limits target engagement in normal tissue an
Autor:
Jonathan W. Goldman, William J. John, Anwar Hossain, Richard Beckmann, Siva Rama Prasad Kambhampati, P. Kellie Turner, Erica L. Johnston, Monte Shaheen, Eric Schaefer, Mariano Provencio, Martin Gutierrez, Daruka Mahadevan, Shadia Jalal, Pilar Garrido, Luis G. Paz-Ares, Karen Kelly, Edward S. Kim
Third part of the appendix
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::242623715c2e35989bbd2a74c402090e
https://doi.org/10.1158/1078-0432.22470783.v1
https://doi.org/10.1158/1078-0432.22470783.v1
Autor:
Jonathan W. Goldman, William J. John, Anwar Hossain, Richard Beckmann, Siva Rama Prasad Kambhampati, P. Kellie Turner, Erica L. Johnston, Monte Shaheen, Eric Schaefer, Mariano Provencio, Martin Gutierrez, Daruka Mahadevan, Shadia Jalal, Pilar Garrido, Luis G. Paz-Ares, Karen Kelly, Edward S. Kim
Purpose: Abemaciclib, a dual inhibitor of cyclin-dependent kinases 4 and 6, has demonstrated preclinical activity in non–small cell lung cancer (NSCLC). A multicenter, nonrandomized, open-label phase Ib study was conducted to test safety, MTD, phar
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::247771de316daddf898dbc0b82a5449e
https://doi.org/10.1158/1078-0432.c.6527679
https://doi.org/10.1158/1078-0432.c.6527679
Autor:
Jonathan W. Goldman, William J. John, Anwar Hossain, Richard Beckmann, Siva Rama Prasad Kambhampati, P. Kellie Turner, Erica L. Johnston, Monte Shaheen, Eric Schaefer, Mariano Provencio, Martin Gutierrez, Daruka Mahadevan, Shadia Jalal, Pilar Garrido, Luis G. Paz-Ares, Karen Kelly, Edward S. Kim
First part of the appendix
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::43cd31f5d7f6762afe34223c2a1cdecd
https://doi.org/10.1158/1078-0432.22470777
https://doi.org/10.1158/1078-0432.22470777
Autor:
Joyce F. Liu, Alison Hannah, Virginia Paton, Susan K. Lyman, Olga Vasiljeva, Ivan A. Zein, Tam Dang, Song Wang, C. Willemien Menke van der Houven van Oordt, Guus A.M.S. van Dongen, Gerben J.C. Zwezerijnen, Marc C. Huisman, Danielle J. Vugts, Iris H.C. Miedema, Stella K. Kim, James J. Harding, Shadia Jalal, Javier Garcia-Corbacho, Misako Nagasaka, Patricia LoRusso, Randy F. Sweis, Rachel E. Sanborn, Nataliya Uboha, Funda Meric-Bernstam, Alexander Spira, Hendrik-Tobias Arkenau, Mary J. Fidler, Valentina Boni
Supplementary Data from Praluzatamab Ravtansine, a CD166-Targeting Antibody–Drug Conjugate, in Patients with Advanced Solid Tumors: An Open-Label Phase I/II Trial
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::20af64024eca128b7e651ebd8e6392cb
https://doi.org/10.1158/1078-0432.22486622
https://doi.org/10.1158/1078-0432.22486622
Autor:
Joyce F. Liu, Alison Hannah, Virginia Paton, Susan K. Lyman, Olga Vasiljeva, Ivan A. Zein, Tam Dang, Song Wang, C. Willemien Menke van der Houven van Oordt, Guus A.M.S. van Dongen, Gerben J.C. Zwezerijnen, Marc C. Huisman, Danielle J. Vugts, Iris H.C. Miedema, Stella K. Kim, James J. Harding, Shadia Jalal, Javier Garcia-Corbacho, Misako Nagasaka, Patricia LoRusso, Randy F. Sweis, Rachel E. Sanborn, Nataliya Uboha, Funda Meric-Bernstam, Alexander Spira, Hendrik-Tobias Arkenau, Mary J. Fidler, Valentina Boni
Purpose:Praluzatamab ravtansine (CX-2009) is a conditionally activated Probody drug conjugate (PDC) comprising an anti-CD166 mAb conjugated to DM4, with a protease-cleavable linker and a peptide mask that limits target engagement in normal tissue and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::87df2ee6ab1f32889e141aee714623c0
https://doi.org/10.1158/1078-0432.c.6532364.v1
https://doi.org/10.1158/1078-0432.c.6532364.v1